Introduction
============

Studies attempting to identify moderators and mediators of treatment ([@b8]; [@b44]), such as baseline/pretreatment predictors of response to antidepressants, have not yielded consistent findings ([@b9]; [@b30]; [@b39]; [@b18]; [@b36]; [@b38]; [@b43], [@b42]; [@b11]; [@b21]; [@b58]; [@b41]; [@b29]; [@b35]; [@b26]; [@b7]; [@b14]; [@b3]; [@b46]). The identified clinical predictors have typically fallen into the following categories: (1) demographic characteristics (gender); (2) illness features (severity at baseline, length of illness, age of onset, length of current episode, number of episodes, longitudinal subtype, endogenicity, melancholia, family history of mood disorders); and (3) social factors (living status, social support).

Numerous illness characteristics have been found to be associated with a positive response to antidepressant medications, including severity of depressive symptoms, depressive subtypes, age at onset of illness, and past history of depressive episodes ([@b1]). Several studies have shown that specific features of psychiatric history and of the current episode of depression influence treatment outcomes. [@b48] found that patients with only a single episode of depression responded slightly better to SSRI treatment than those with recurrent episodes (sertraline: 62% vs 52%; amitriptyline: 66% vs 62%). Additionally, patients with melancholic features responded slightly better than those without such features (sertraline: 56% vs 50%; amitriptyline: 63% vs 59%). Based on a sample of patients with recurrent depression, [@b30] also found age, symptom severity, and number of previous episodes associated with time to sustained treatment response. The most extensively studied area of treatment predictors includes history of illness characteristics, such as number of previous episodes, length of illness, and the presence of either single episode or recurrent longitudinal subtypes. However, findings are not consistent across all studies. [@b35] demonstrated that the baseline Hamilton Rating Scale for Depression (HRSD) score was of greater significance in predicting recovery than other variables, such as premorbid history, symptomatology, and endogenous features ([@b20]). [@b30] found that patients with high HRSD scores tended to take longer to stabilize than patients with lower scores. However, [@b47] were unable to replicate this finding. Conversely, patients with less severe depressive illness have been shown to be more likely to respond to amitriptyline or imipramine than those with severe depressive illness ([@b18]). Family history has also been found to be a prognostic indicator of outcomes. When comparing patients who experience full interepisodic recovery with partial and non-interepisodic recovery patients, [@b2] found that patients with a family history (first degree biological relative) of affective disorders were more likely to have an incomplete recovery when treated with tricyclic antidepressants.

In addition to illness features that predict treatment response, researchers have attempted to examine the effects of social or situational factors on treatment outcome. Direct measures of social support and functioning, ie, Social Adjustment Scale, Social and Occupational Functioning Assessment Scale ([@b59]; [@b6]), and indirect measures such as living status have been found to be positively related to response. [@b58] directly tested the effects of social support on response after 6 weeks of medication treatment. They found that patients treated with imipramine, with higher levels of social support showed a greater percent decrease in HRSD scores than patients with lower levels of social support. [@b54] obtained similar results in a population of patients with non-melancholic depression, and found higher levels of social support in those patients who responded favorably to treatment.

The vast majority of research evaluating the relationship between social support and major depressive disorder (MDD) has largely focused on the role played by social support in improving clinical outcomes in general. Research has not focused as much on patients being treated specifically with antidepressant medications or psychotherapy. The relationship between social support and psychological wellbeing has long been documented ([@b45]; [@b22]; [@b4]; [@b13]). Studies have suggested that social support plays a significant role in mediating the development of depressive symptoms by buffering the effects of negative life events ([@b5]; [@b10]; [@b27]; [@b60]). [@b12] found that patients with a longer course of illness, as manifested by multiple recurrent episodes, reported significantly lower levels of social support than patients with a shorter course of illness. [@b25] found that the psychological support provided by a spouse was significant, with high levels of support being associated with positive treatment outcomes. In a sample of 552 women aged 18--65, [@b15] found that lack of intimacy with a spouse or cohabitant and lack of a confidant were associated with clinically significant levels of depression. [@b36] found, in a 9-month post-hospitalization follow-up of patients with unipolar depression, that patients with higher levels of marital discord had significantly higher relapse rates. [@b17] found higher levels of marital distress in depressed females than in community controls. Interestingly, there appear to be gender differences in the reporting of marital distress, with depressed females reporting higher levels of marital distress than their partners ([@b23]; [@b19]). In their 1992 study, Goering et al found that in a population of women with MDD, few demographic or clinical factors were related to the course of symptoms over the 6-month study period. Recovery was predicted based on the patients' ratings of their current marital relationship and by the spousal rating of their premorbid relationship.

The purpose of this study was to identify baseline demographic, illness, and social features that predict response to an antidepressant medication, nefazodone, in patients with MDD. The demographic, illness, and social feature predictors evaluated were: gender, age of onset, severity at baseline, length of illness, length of current episode, number of episodes, longitudinal subtype, endogenicity, melancholia, family history of mood disorders, and living status.

Methods
=======

Subjects
--------

Participants in this study were 97 outpatients with MDD: 59 females and 38 males, age 38.5 ± 10.0 (mean ± SD). They were treated for up to sixteen weeks with nefazodone in the Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, USA. This sample has been reported as part of a larger multicenter trial ([@b56]). Prior to interview, all patients provided written informed consent. All participants met the Structured Clinical Interview for DSM-III-R (SCID) ([@b53]) criteria for MDD and were 18 years of age or older. The duration of the current major depressive episode was ≥ 6 months. Patients with bipolar disorder, seasonal affective disorder, substance abuse or dependence disorders, as well as those with delusions or hallucinations during the current episode, were excluded. Patients judged to be at serious risk of suicide and those with a concurrent diagnosis of organic mental syndrome, schizophrenia, or any other psychotic disorder, were not included in the sample. All patients had a 17-item Hamilton Rating Scale for Depression (HRSD~17~) ([@b32], [@b33]) score ≥ 20 at the baseline evaluation. See [Table 1](#tbl1){ref-type="table"}.

###### 

Predictors of response to antidepressants: baseline

  Predictors of response                                    n    Mean   SD     \%
  --------------------------------------------------------- ---- ------ ------ -----------
  Age                                                       97   38.5   10.0   
  Females/Males                                             97                 60.8/39.2
  Marital status                                            97                 
  Single                                                                       19.6
  Engaged                                                                      1.0
  Married                                                                      37.1
  Cohabiting                                                                   8.2
  Divorced                                                                     32.0
  Widowed                                                                      2.1
  HRSD at baseline                                          97   23.9   2.1    
  Age at onset                                              96   25.1   11.0   
  Length of illness[a](#tf1-1){ref-type="table-fn"}         96   13.2   9.7    
  Length of current episode                                 97   67.0   75.8   
  Number of episodes                                        95   2.3    1.9    
  Single/Recurrent                                          95                 40.0/60.0
  Endogenous/Nonendogenous                                  81                 42.0/58.0
  Melancholic/Nonmelancholic                                97                 43.3/56.7
  Family history of affective disorder(Positive/Negative)   94                 36.2/63.8

Months

**Abbreviations:** HRSD, Hamilton Rating Scale for Depression.

Procedures
----------

Patients were evaluated at baseline using a SCID to obtain demographic (age and gender), social (living status), and illness features (length of episode, depressive subtype, age at onset, recurrence, length of illness, number of episodes, family history of depression). Melancholia was characterized based on the SCID ([@b53]), and endogenicity was defined using the Research Diagnostic Criteria ([@b52]). Symptom severity was assessed at baseline using the HRSD~17~ and the thirty-item Inventory of Depressive Symptomatology -- Clinician Rated (IDS-C~30~) ([@b49], [@b50]) and again with the HRSD~17~ at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 16. Nefazodone was administered twice daily for 12 weeks. Dosages were titrated up to 400 mg/day by the end of the second week. Patients not responding to the initial titration schedule were titrated to 500 or 600 mg/day after week 3. Patients were restricted from concomitant use of other drugs except lorazepam, temazepam, or oxazepam.

Statistical analysis
--------------------

Cox's proportional hazard models ([@b16]) were used to test for differences in treatment response for a series of demographic, social support, and illness features. The demographic characteristic and social support predictors evaluated were gender and living status, respectively. Illness features included length and severity of current episode, length of illness, number of episodes, age at onset, longitudinal subtype, endogenicity ([@b52]), melancholia ([@b53]), and family history of mood disorders. For these analyses response to treatment was defined as a \>50% reduction in the baseline HRSD total score.

Results
=======

Demographic and social features
-------------------------------

The analysis of living status indicated better response to treatment for the married patients (married or cohabiting) than those patients living alone (single, engaged, divorced, widowed): 84% and 51%, respectively (χ^2^ = 6.9, df = 1, p \< 0.009). While the response rates were similar in the first few weeks of treatment, after week 4, married patients show clearly higher rates of response than the unmarried patients (see [Figure 1](#fig1){ref-type="fig"}). This result is qualified by differences in the dropout rates (single, 34%; married, 14%). There was no statistically significant effect for gender. See [Table 2](#tbl2){ref-type="table"}.

![Estimated likelihood of response based on Cox's regression analyses for living status.](ndt0101-51-01){#fig1}

###### 

Predictors of response to antidepressants and baseline HRSD

                                                           Baseline HRSD   
  --------------------------------------------------- ---- --------------- -----
  Gender                                                                   
   Female                                             59   23.9            2.2
   Male                                               38   23.8            2.1
  Marital status[a](#tf2-1){ref-type="table-fn"}                           
   Unmarried                                          53   23.9            1.9
   Married                                            44   23.8            2.4
  Age at onset                                                             
   0--19                                              40   23.8            2.1
   20+                                                56   23.9            2.2
  Length of illness[a](#tf2-1){ref-type="table-fn"}                        
   0--9                                               42   24.1            2.4
   10+                                                54   23.7            1.9
  Length of current episode                                                
   0--48                                              50   24.0            2.2
   49+                                                47   23.7            2.1
  Number of episodes                                                       
   1                                                  40   23.9            2.1
   2                                                  26   23.9            2.6
   3+                                                 30   23.8            1.9
  Single                                              38   23.9            2.1
  Recurrent                                           57   23.8            2.2
  Endogenous                                          34   23.3            1.4
  Nonendogenous                                       47   24.4            2.7
  Melancholic                                         42   24.5            2.5
  Nonmelancholic                                      55   23.4            1.7
  Family history of affective disorder                                     
   Positive                                           34   23.8            2.4
   Negative                                           60   23.9            2.0

p \< 0.05 comparing 2 subgroups (survival analysis).

**Abbreviations:** HRSD, Hamilton Rating Scale for Depression.

Illness features
----------------

Four predictors were used to create a test for differences in response based on characteristics of the current depressive episode: severity (HRSD score 20--23 vs HRSD score ≥ 24); length of the current episode (0--48 months vs \> 49 months (this median split provided sample size for the two groups to make a reasonable comparison)); endogenous vs nonendogenous; and melancholic vs nonmelancholic. Length of the current episode revealed that patients whose current episode was less than 4 years were more likely to respond (70%) than those with longer current episodes (62%). This effect was marginally significant (χ^2^ = 3.2, df = 1, p \< 0.08). Dropout rates were about the same for these two groups (28% and 26%, respectively). Since chronic depression has been defined as episodes lasting 2 years or more, a secondary analysis was conducted using a 24-month threshold to distinguish short vs longer current episodes. No statistically significant differences were found. Baseline severity, endogenicity, and the presence of melancholia were not significantly related to treatment response.

Four measures were used to define strata based on history of illness (single vs recurrent; age at onset: 1--19 vs 20 or older; length of illness: 0--9 years vs \> 10 years; and number of episodes: 1 vs 2 vs 3 or more). Length of illness was significantly related (χ^2^ = 5.2, df = 1, p \< 0.03) to outcome. Patients with shorter illnesses were more likely to respond than those with longer illnesses (see [Figure 2](#fig2){ref-type="fig"}). Single versus recurrent depression, age of onset, and number of episodes were not significantly related to treatment response.

![Estimated likelihood of response based on Cox's regression analyses for length of illness and family history of depression.](ndt0101-51-02){#fig2}

Strata were created based on a positive versus negative family history of major mood disorders in first-degree relatives. There was a significant difference based on family history (χ^2^ = 4.6, df = 1, p \< 0.04). Patients with a negative family history were more likely to respond (77%) than those with a positive family history (62%) (see [Figure 2](#fig2){ref-type="fig"}). Dropout rates before completing 16 weeks of treatment were similar (21% and 30%, respectively).

Analyses of combined predictors
-------------------------------

To explore the relationships between individual baseline features that predicted response, survival analysis was conducted and included all three individual predictors: marital status, length of illness, and family history. Once living status entered the model, no other predictors significantly improved the model. Thus, there was substantial overlap between these individual predictors, as might be expected in this relatively small sample. The parallel analyses conducted using an HRSD score ≥ 10 criteria produced the same results for living status (χ^2^ = 7.7, df = 1, p \< 0.006) and length of illness (χ^2^ = 4.3, df = 1, p \< 0.04). A significant difference, as opposed to a marginal difference, was found for length of episode (χ^2^ = 4.3, df = 1, p \< 0.04). Only one major difference was found for the single vs recurrent depression groups. A significant difference was found using this response criterion (χ^2^ = 4.6, df = 1, p \< 0.04). Patients with a recurrent history responded better than those in their first episode.

Discussion
==========

The results of this study suggest that three easily discernable patient characteristics can help predict a patient's response to antidepressant medication, in this case, nefazodone. The characteristics found to be most useful were, living status, total length of illness, and family history of depression. The findings associated with illness features are consistent with previous studies reporting longer current episodes associated with a lower likelihood of response to antidepressants ([@b9]; [@b51]; [@b40], [@b41]).

Although more elaborate methods of outcome prediction such as receptor analysis or neuroimaging ([@b24]) may be useful, they have not yet led to consistent findings and are very likely not to be practical in routine clinical practice. The results of this study suggest, simple, easy to obtain data, such as marital status, show great promise in the prediction of response to antidepressant treatment. Interestingly, in our sample, being married or living together appeared to have a profound positive effect on the overall response rates, with married or cohabiting patients meeting criteria for treatment response with greater frequency than their single cohorts. Living status also had an impact on the patients' willingness to stay in treatment. The married/cohabiting group remained in treatment longer even in the absence of response, a finding consistent with [@b31] who found patients living alone were more likely to drop out of treatment. Numerous drug utilization studies have shown that over 45%--50% of patients who start an antidepressant are not in treatment by 3 months, suggesting a strong need to be able to preemptively identify predictors of not only response but also dropouts. While not all studies have found social support to be a significant predicator of treatment outcome ([@b34]; [@b27]), the majority of the studies have suggested social support and even more specifically marital status as positive predictors of response. The quality of the marital relationship also provides a significant aid in predicting treatment response. Moreover, recent data from a number of studies ([@b37]; [@b57]; [@b55]) suggest there is a clear benefit for a disease management approach in the treatment of depression. These studies have emphasized more frequent patient contact as well as more robust psychosocial and educational support for patients to enhance adherence, improve the patient's ability to self-monitor their symptoms, and increase patients' understanding of the chronic medical illness nature of their depressive disorders. These data thus provide another dimension of evidence that optimal outcome can be enhanced if pharmacotherapy is augmented with social support.

The current study is limited by several factors including a moderate sample size, the use of only one antidepressant medication, and the lack of a placebo control group. It is also possible that factors indicating a chronic and or severe disorder like length of illness may predict poorer outcome irrespective of the treatment(s) used. Moreover, it is also likely that social support, life stressors, and family history of psychiatric comorbidity are indicators of positive outcome for MDD across various treatment modalities and may also increase the chances of spontaneous response. Therefore, in the absence of a placebo or an active control, the demographic and clinical features identified may be thought of as good prognostic predictors of outcome independent of treatment modality. Despite these limitations, the current study does provide additional support for the hypothesis that easy to identify patient factors may be able to significantly improve the quality of patient care by increasing physician efficiency when prescribing anti-depressant medications. These clinical predictors, although not prescriptive, can assist in treatment planning and aid with patient education regarding potential outcomes. Of the three clinical predictors identified (living status, total length of illness, and family history of depression), living status appears to be the most promising mediator of treatment outcome. Future study of clinical predictors of treatment response for emerging antidepressant medications should include social features, such as living status and an assessment of the quality of relationships, in addition to the commonly used demographic and illness features in predictor analyses.
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